oral D1 modulator
Ph. I candidate for neurological disorders
opt. against DDI w/ hepatocyte Cl assay
J. Med. Chem.
Eli Lilly and Company
Context. LY3154885 (Eli Lilly and Company) is an oral D1 modulator. Lilly recently completed several clinical trials with LY3154207 (mevidalen), the first D1 positive allosteric modulator (D1PAM) with published…